MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance-Reference-Cited by-同舟云学术

MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance

Published:2021-05-18 Issue:12 Volume:35 Page:3394-3405
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

van der Zwet Jordy C. G.^ORCID,Buijs-Gladdines Jessica G. C. A. M.,Cordo’ Valentina^ORCID,Debets Donna O.,Smits Willem K.,Chen Zhongli,Dylus Jelle,Zaman Guido J. R.,Altelaar Maarten,Oshima Koichi,Bornhauser Beat^ORCID,Bourquin Jean-Pierre,Cools Jan^ORCID,Ferrando Adolfo A.^ORCID,Vormoor Josef^ORCID,Pieters Rob,Vormoor Britta,Meijerink Jules P. P.^ORCID

Funder

Stichting Kinderen Kankervrij

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-021-01291-5.pdf

Reference51 articles.

1. Pieters R, de Groot-Kruseman H, Van der Velden V, Fiocco M, van den Berg H, de Bont E, et al. Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: study ALL10 From the Dutch Childhood Oncology Group. J Clin Oncol. 2016;34:2591–601.

2. Conter V, Valsecchi MG, Parasole R, Putti MC, Locatelli F, Barisone E, et al. Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study. Blood. 2014;123:1470–8.

3. Lauten M, Moricke A, Beier R, Zimmermann M, Stanulla M, Meissner B, et al. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia. Haematologica. 2012;97:1048–56.